Preventing liver and heart disease through lifestyle changes
Cardiovascular Diseases (CVD) and Nonalcoholic Fatty Liver Diseases (NAFLD) Among Gallstone and Cholecystectomy Patients and the Impact of a Novel Diet and Muscle Training Program
This study is testing a lifestyle program to see if it can help people with gallstone disease and fatty liver disease prevent heart and liver problems by improving their diet and exercise habits.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 45 Years to 60 Years |
| Sex | All |
| Sponsor | Pontificia Universidad Catolica de Chile Academic / other |
| Locations | 1 site (Molina, Maule Region) |
| Trial ID | NCT05618626 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to prevent non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) by implementing a lifestyle intervention program called MAUCO+. The study will involve 300 participants who will be randomly assigned to either a control group receiving standard recommendations or an experimental group receiving tailored exercise and dietary interventions. The goal is to improve physical fitness, body composition, and metabolic health through supervised exercise and an anti-inflammatory diet. The trial specifically targets individuals with gallstone disease and varying degrees of NAFLD.
Who should consider this trial
Good fit: Ideal candidates include individuals with gallstone disease and varying degrees of NAFLD who are able to participate in lifestyle modifications.
Not a fit: Patients with significant comorbidities or physical limitations that prevent them from engaging in exercise may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce the risk of liver and heart diseases in participants.
How similar studies have performed: Previous studies have shown positive outcomes with lifestyle interventions for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * With and without gallstones disease * With various degrees of NAFLD (none too severe) Exclusion Criteria: * Any significant comorbidity or physical limitation to undergo resistance exercise program * Use of medications that alter muscle mass (e.g., corticosteroids) * History of hepatitis B or C * Use of hepatotoxic drugs
Where this trial is running
Molina, Maule Region
- Centro MAUCO+ — Molina, Maule Region, Chile (Recruiting)
Study contacts
- Principal investigator: Catterina Ferreccio, MD — Pontificia Universidad Catolica de Chile
- Study coordinator: Laura A Huidobro, PhD
- Email: leahuidobro@gmail.com
- Phone: +56 9 9219 6618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.